Table 2.

Changes from baseline in secondary efficacy variables (ITT population)

Variable	Topical finasteride (N = 105)	Placebo (N = 97)	Oral finasteride (N = 48)
Hair width, μm [adjusted mean (SE)]
Week 24	−0.81 (0.35)	−1.53 (0.37)	0.72 (0.47)
Self‐administered MHGQ overall score† [adjusted mean (SE)]
Week 24	2.8 (0.75)	3.0 (0.95)	2.9 (0.89)
Investigator‐assessed change in patient hair growth/loss‡ [adjusted mean (SE)]
Week 24	0.8 (0.09)*	0.3 (0.09)	0.7 (0.12)
Blinded‐assessor change in patient hair growth/loss‡ [adjusted mean (SE)]
Week 24	0.2 (0.09)	0.1 (0.09)	0.3 (0.12)

ITT, intention to treat; MHGQ, Male Hair Growth Questionnaire; SE, standard error.

^* P < 0.001 vs. placebo.

^†Assessed on a 5‐point scale from 1 = very satisfied to 5 = very dissatisfied.

^‡ Assessed on a 7‐point scale from −3 = greatly decreased to +3 = greatly increased.